Stocksigma LogoStocksigma Logo

Accretion Pharmaceuticals Reports Strong H1 FY27 Performance with 72.6% PAT Surge

Accretion Pharmaceuticals reported revenue from operations of ₹5,504.10 lakhs for the half-year ended 30th Sep'26, up 25.8% YoY from ₹4,373.62 lakhs

Accretion Pharmaceuticals Reports Strong H1 FY27 Performance with 72.6% PAT Surge

Accretion Pharmaceuticals Ltd · Outcome · 02 Nov 2026, 5:38 pm

Accretion Pharmaceuticals Reports Strong H1 FY27 Performance with 72.6% PAT Surge Accretion Pharmaceuticals reported revenue from operations of ₹5,504.10 lakhs for the half-year ended 30th Sep'26, up 25.8% YoY from ₹4,373.62 lakhs. Profit Before Tax climbed 69.2% YoY to ₹1,084.49 lakhs compared to ₹641.07 lakhs in H1 FY26. Net profit surged 72.6% YoY to ₹820.14 lakhs from ₹475.22 lakhs, expanding diluted EPS to ₹7.38 from ₹4.61. Operating cash outflow stood at ₹312.14 lakhs due to working capital additions. Net worth reached ₹6,291.00 lakhs with total borrowings at ₹1,673.70 lakhs.

Original exchange filing (PDF)

More announcements from Accretion Pharmaceuticals Ltd

All Accretion Pharmaceuticals Ltd announcements